세계의 음경암 치료 시장(2023-2030년)

Overview

The Global Penile Cancer Treatment Market reached US$ 2.3 billion in 2022 and is expected to reach US$ 3.2 billion by 2030 growing with a CAGR of 5.6% during the forecast period 2023-2030.

The penile cancer treatment market is driven by factors such as increasing incidence of penile cancer, advancements in treatment options, awareness, and early detection, supportive government initiatives, increasing healthcare expenditure, and personalized medicine.

A subset of the larger oncology market, the penile cancer treatment market focuses on offering medicines and medical interventions to people who have been diagnosed with the disease. There are many different types of treatment options available on the market, including surgery, radiation therapy, chemotherapy, targeted medicines, and immunotherapy.

Dynamics

The Increasing Incidence of Penile Cancer Treatment is Driving the Global Penile Cancer Treatment Market Growth

As per the article published in Frontiers in 2022, the anticipated global incidence of penile cancer in 2020 is 36,068 cases (0.92 incidences per 100,000 individuals). However, the incidence of malignant tumors might be up to 6.1 cases/100,000 people in underdeveloped nations. Squamous cell carcinoma (SCC) is the most common histology and is responsible for almost all occurrences. With curative surgery, overall survival (OS) in individuals with early disease without nodal involvement is 96% in 10 years, compared to 50% and 12%, respectively, in 5 years for patients with regional node disease and distant metastatic disease.

With typical chemotherapeutic toxicities and modest survival outcomes, both in the treatment of advanced disease and in the neoadjuvant setting, cytotoxic chemotherapy plays a significant role in systemic treatment. It primarily consists of platinum and taxane combination regimens.

Government Initiatives are Driving the Global Penile Cancer Treatment Market Growth

As per the article published in Nature Reviews Urology in 2022, in order to standardize care and therapies across nations, uncover the critical clinical gaps around uncommon genitourinary cancers, such as penile cancer, and increase the life expectancy of these patients, international cooperation is urgently required. Global Society of Rare Genito-urinary Tumors (GSRGT) seeks to achieve these objectives. The initial goal of the GSRGT is to incorporate developing nations, which are a significant source of uncommon tumors but were previously excluded from registries and studies.

For instance, tertiary care facilities in South America, Africa, India, and Asia collaborate with academic centers in Europe and North America to enable rapid and thorough data recovery from all corners of the world. In order to provide patients with the best available evidence-based treatments, GSRGT will encourage cooperation between doctors from various nations in order to spread up-to-date and easily accessible information about penile cancer. This will be accomplished through working with reputable medical societies.

Side Effects Associated with Penile Cancer Treatment are Hampering the Global Penile Cancer Treatment Market Growth

Chemotherapy medications target rapidly dividing cells, which is why they are effective against cancer cells. However, some cells in the body divide quickly, including those in the bone marrow (where new blood cells are produced), the lining of the mouth and intestines, and the hair follicles. These cells can be impacted by chemotherapy, which may have unfavorable repercussions.

The type, dosage, and duration of the chemotherapy medications affect the adverse effects. Typical negative consequences include loss of hair mouth ulcers decrease in appetite, vomiting, nauseous, constipation or diarrhea, infection risk is increased (because of decreased white blood cell levels), and low blood platelet counts can cause easy bruising or bleeding as well as fatigue.

In addition, the lack of a thorough understanding of the molecular biology and genomic and epigenomic alterations involved in carcinogenesis and tumor progression, as well as the difficulty in enrolling patients for prospective clinical trials, have always hampered advances in the treatment of rare tumors like penile cancer.

Segment Analysis

The global penile cancer treatment market is segmented based on type, treatment, end-user and region.

The Chemotherapy Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period

The chemotherapy segment accounted for the highest market stake accounting for approximately 37.6% of the penile cancer treatment market in 2022. Cancer-curing medications are administered orally or by venous injections during systemic chemotherapy. These medications reach cancer cells all around the body via the bloodstream. Penile tumors that have migrated to distant organs or lymph nodes are the most common candidates for this treatment. Before surgery, tumors may be shrunk with chemotherapy to make them easier to remove.

Chemotherapy is administered by doctors in cycles, with a rest interval following each cycle to allow the body to heal. Chemotherapy cycles typically last 3 to 4 weeks. Cisplatin, Fluorouracil (5-FU), Paclitaxel (Taxol), Ifosfamide (Ifex), Mitomycin C, and Capecitabine (Xeloda) are a few of the medications used to treat penile cancer. In order to treat penile cancer that has progressed to lymph nodes or other organs, 2 or more of these medications are frequently combined. Cisplatin plus 5-FU is one of the most often used combos.

Geographical Penetration

North America Holds a Dominant Position in the Global Penile Cancer Treatment Market

North America is estimated to hold around 1/3rd of the total market share throughout the forecast period. The active major players are driving the market in the North American region. Penile cancer is a rare form of cancer, especially in developed countries. Over 2000 new cases are reported annually in the United States, with rates of fewer than 1 per 100,000 men. However, there is a much higher occurrence in underdeveloped countries, where there is also a lack of therapeutic knowledge and access to care, which contributes to an unmet clinical need. The link with human papillomavirus infection, which may be present in as many as 50% of all penile carcinomas, is the most notable risk factor for penile cancer.

Older men are more likely to get penile cancer, and the incidence rate continually rises with age. Penile cancer most frequently affects men between the ages of 50 and 70, with a mean age of 67 in the United States of America.

Competitive Landscape

The major global players in the market include: Merck, GlaxoSmithKline, Pfizer, Bristol-Myers Squibb, Roche, Novartis, Shanghai Junshi Biosciences Co., Ltd., Innovent Biologics, Jiangsu Hengrui Medicine Co., Ltd., and BeiGene Ltd. among others.

COVID-19 Impact Analysis

Russia-Ukraine Conflict Analysis

The Russia-Ukraine war may affect the penile cancer treatment market due to a lack of facilities being impacted during times of geopolitical instability and economic uncertainty. Healthcare workers are frequently displaced, medical supply lines are disrupted, and healthcare facilities are damaged during armed conflicts. The impacted people in Russia and Ukraine have less access to cancer detection and treatment options as a result.

Artificial Intelligence Impact Analysis

Artificial intelligence (AI) is increasingly being used in the penile cancer treatment market to improve various aspects of data analysis. AI can help oncologists create individualised treatment plans for patients with penile cancer. AI can make therapeutic recommendations that are specific to each patient by examining patient data, medical history, and the results of similar instances.

By Type

• Squamous Cell Cancer of Penis
• Adenocarcinoma of Penis
• Basal Cell Cancer of Penis
• Others

By Treatment

• Chemotherapy
• Radiation Therapy
• Biological Therapy
• Photodynamic Therapy
• Antibiotic Therapy

By End-user

• Hospitals
• Specialty Clinics
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Why Purchase the Report?

• To visualize the global penile cancer treatment market segmentation based on the type, treatment, end-user and region and understand key commercial assets and players
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of penile cancer treatment market-level with all segments
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study
• Product mapping available as excel consisting of key products of all the major players

The global penile cancer treatment market report would provide approximately 69 tables, 71 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Treatment
• 3.3. Snippet by End-user
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising Incidence of Penile Cancer Treatment
  • 4.1.2. Restraints
    • 4.1.2.1. Side effects associated with Penile Cancer Treatment
  • 4.1.3. Opportunity
    • 4.1.3.1. Technological advancements
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Unmet Needs
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers' Strategic Initiatives
• 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Analysis

9. By Type

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.1.2. Market Attractiveness Index, By Type
• 9.2. Squamous Cell Cancer of Penis*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Adenocarcinoma of Penis
• 9.4. Basal Cell Cancer of Penis
• 9.5. Others

10. By Treatment

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 10.1.2. Market Attractiveness Index, By Treatment
• 10.2. Chemotherapy*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Radiation Therapy
• 10.4. Biological Therapy
• 10.5. Photodynamic Therapy
• 10.6. Antibiotic Therapy

11. By End-user

• 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
• 11.1.2. Market Attractiveness Index, By End-user
• 11.2. Hospitals*
  • 11.2.1. Introduction
  • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 11.3. Specialty Clinics
• 11.4. Homecare
• 11.5. Others

12. By Region

• 12.1. Introduction
  • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 12.1.2. Market Attractiveness Index, By Region
• 12.2. North America
  • 12.2.1. Introduction
  • 12.2.2. Key Region-Specific Dynamics
  • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.2.6.1. U.S.
    • 12.2.6.2. Canada
    • 12.2.6.3. Mexico
• 12.3. Europe
  • 12.3.1. Introduction
  • 12.3.2. Key Region-Specific Dynamics
  • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.3.6.1. Germany
    • 12.3.6.2. U.K.
    • 12.3.6.3. France
    • 12.3.6.4. Italy
    • 12.3.6.5. Spain
    • 12.3.6.6. Rest of Europe
• 12.4. South America
  • 12.4.1. Introduction
  • 12.4.2. Key Region-Specific Dynamics
  • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.4.6.1. Brazil
    • 12.4.6.2. Argentina
    • 12.4.6.3. Rest of South America
• 12.5. Asia-Pacific
  • 12.5.1. Introduction
  • 12.5.2. Key Region-Specific Dynamics
  • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.5.6.1. China
    • 12.5.6.2. India
    • 12.5.6.3. Japan
    • 12.5.6.4. Australia
    • 12.5.6.5. Rest of Asia-Pacific
• 12.6. Middle East and Africa
  • 12.6.1. Introduction
  • 12.6.2. Key Region-Specific Dynamics
  • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

13. Competitive Landscape

• 13.1. Competitive Scenario
• 13.2. Product Benchmarking
• 13.3. Company Share Analysis
• 13.4. Key Developments and Strategies

14. Company Profiles

• 14.1. Merck*
  • 14.1.1. Company Overview
  • 14.1.2. Product Portfolio and Description
  • 14.1.3. Financial Overview
  • 14.1.4. Key Developments
• 14.2. GlaxoSmithKline
• 14.3. Pfizer
• 14.4. Bristol-Myers Squibb
• 14.5. Roche
• 14.6. Novartis
• 14.7. Shanghai Junshi Biosciences Co., Ltd.
• 14.8. Innovent Biologics
• 14.9. Jiangsu Hengrui Medicine Co., Ltd.
• 14.10. BeiGene Ltd.

LIST NOT EXHAUSTIVE

15. Appendix

• 15.1. About Us and Services
• 15.2. Contact Us